Skip to main content
. 2023 Jan 5;13:1070688. doi: 10.3389/fmicb.2022.1070688

Table 2.

Perioperative variables and infection status.

Total (N = 83) NIAC (N = 66) IAC (N = 17) Value of p
Surgical diagnosis 0.462
Tumor 37(44.6) 30(45.5) 7(41.2)
Gastrointestinal perforation without tumor 19(22.9) 13(19.4) 6(35.3)
Postoperative gastrointestinal anastomosis leakage 12(14.5) 9(13.6) 3(17.6)
Intestinal obstruction without tumor 5(6.0) 5(7.6) 0(0.0)
Othersa 10(12.0) 9(13.6) 1(5.9)
Site of abdominal surgery 0.001
Upper gastrointestinal tract 23 (27.7) 13 (19.7) 10 (58.8)
Non-upper gastrointestinal tract 60 (72.3) 53 (80.3) 7 (41.2)
Surgery type 1.000
Emergency 64 (77.1) 51 (77.3) 13 (76.5)
Elective 19 (22.9) 15 (22.7) 4 (22.9)
ASA classification IV or V 34 (41.0) 29 (43.9) 5 (29.4) 0.277
ICU admission
APACHE II score 15 (11–19) 15 (11–19) 17 (12–20) 0.432
SOFA score 6 (4–9) 6.5 (4–9) 6 (4–8.5) 0.75
Temperature, °C 37.4 (36.7–37.9) 37.4 (36.7–37.9) 37.5 (36.8–38.0) 0.631
WBC (×109/L) 9.8 (6.8–14.1) 10.1 (8.0–14.1) 8.4 (4.4–14.4) 0.147
NE, % 89.5 (85.2–93.1) 88.2 (84.6–92.6) 92.0 (89.0–94.3) 0.037
PCT (ng/ml)b 3.8 (1.0–15.1) 4.0 (0.6–15.9) 3.2 (1.4–7.4) 0.909
CRP (ng/ml)c 133.3 (80.2–193.7) 142.0 (84.8–196.0) 69.3 (57.1–159.5) 0.088
Antifungal treatment 53 (63.9) 37 (56.1) 16 (94.1) 0.004
Initial antifungal treatment d 0.001
Preventive therapies 2/53 (3.8) 2/37 (5.4) 0/16 (0.0)
Empirical therapies 42/53 (79.2) 33/37 (89.2) 9/16 (56.3)
Preemptive therapies 3/53 (5.7) 2/37 (5.4) 1/16 (33.3)
Target therapies 6/53 (11.3) 0/37 (0.0) 6/16 (37.5)

Results are presented as mean ± SD or median (interquartile range), or n (%). aOthers include intestinal ischemia, acute pancreatitis, choledocholithiasis, acute appendicitis, intra-abdominal hemorrhage, and postoperative intra-abdominal infection; bN = 80; cN = 62; dTwo patients began antifungal treatment before percutaneous drainage, and one patient began antifungal treatment before ICU admission. ASA, American Society of Anesthesiology; APACHE, acute physiology and chronic health evaluation; SOFA, sepsis-related organ failure assessment; WBC, white blood cell, NE neutrophils; CRP, C-reaction protein; PCT, procalcitonin.